Research Article
Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
Table 1
Advanced melanoma patients’ characteristics before ACT.
| Patient | Sex | At diagnosis | Advanced or metastatic disease | Treatments before TILs | BRAF | c-KIT | Localization | Breslow (mm) | AJCC Stage | Age | Metastasis diagnosis to TIL injection (years) | Chemotherapy | Anti-CTLA4 (ipilimumab to TILs time, months) | Others | Status | Status |
| 1 | F | Scalp | 3 | II | 15 | 1.6 | Fote | Ipilimumab [16] | RT, Surg | WT | WT | 2 | F | Left ankle | 2 | NA | 36 | 1.6 | DCB | BMSa [17] | | V600E | WT | 3 | F | Back | 5 | II | 68 | 2.4 | DCB, carbo, cycloP | BMSa [27] | | V600E | WT | 4 | F | Back | 5.2 | II | 59 | 5.3 | DCB, carbo, vind, temo | | Vac | V600E | WT | 5 | F | Left leg | 1.21 | NA | 38 | 2.5 | DCB, carbo, paclitaxel | | RT | NA | WT | 6 | F | Left foot | 2.85 | II | 76 | 0.1 | None | None | None | V600E | WT | 7 | F | Left leg | 0.74 | I | 62 | 10.1 | DCB, carbo | | Vac, AZD | WT | Mutated | 8 | M | Right foot | 5.75 | II | 87 | 0.8 | DCB, temo | Ipilimumab [5] | Vac | WT | WT | 9 | F | Left leg | 1.85 | I | 82 | 0.9 | DCB | | | WT | WT | 10 | F | Right leg | 3 | II | 63 | 10.75 | | | Vac | WT | WT |
|
|
AJCC: American Joint Committee on Cancer; AZD: NCT00338130 study (AstraZeneca AZD 6244 versus temo); BMS: study (dacarbazine + ipilimumab 10 mg/kg versus dacarbazine + placebo); carbo: carboplatin; cycloP: cyclophosphamide; DCB: dacarbazine; Fote: fotemustine; NA: data not available; RT: radiotherapy; Surg: surgery; temo: temozolomide; Vac: vaccination; vind: vindesine; WT: wild type. aPatient in the dacarbazine + ipi arm. |